Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole in Hepatopulmonary Syndrome
NCT04577001Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Feb 2021
- Primary completion
- Mar 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatopulmonary syndrome (HPS) comparing Letrozole Group with Placebo Group (2 arms). Primary endpoint: Alveolar-Arterial Oxygen Gradient at 6 months. Started Feb 2021; status: terminated.
02
Drugs
letrozole
03
Conditions
hepatopulmonary syndrome (HPS)
Beyond the preview
Go deeper on NCT04577001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04577001.